ArticleEndocrine, metabolic & immune disorders drug targets2025
Revealing Fibrosis Genes as Biomarkers of Ulcerative Colitis: A Bioinformatics Study Based on ScRNA and Bulk RNA Datasets.
Article in Endocrine, metabolic & immune disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epithelial cell-based multi-omics integration identifies SPINK5 and SRI as novel diagnostic biomarkers for ulcerative colitis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to uncover biomarkers associated with fibroblasts to diagnose ulcerative colitis (UC) and predict sensitivity to TNFα inhibitors.
methodsWe identified fibrosis-related genes by analyzing eight bulk RNA and one single-cell RNA sequencing dataset from UC patients. Three machine learning algorithms were employed to identify common significant genes. We utilized five machine learning models, namely Random Forest (RF), Support Vector Machine (SVM), Xgboost, Multilayer Perceptron (MLP), and Logistic Regression, to develop diagnostic models for UC. Following hyperparameter tweaking using grid search, we evaluated Matthew's Correlation Coefficient (MCC) of each model on the validation set. Finally, we identified five hub genes in UC patients and evaluated their response to infliximab or golimumab.
resultsWe identified 23 genes associated with fibroblasts. Further analysis using three ML models revealed BIRC3, IFITM2, ANXA1, ISG20, and MSN as critical fibroblast genes. Following hyperparameter adjustment, the SVM model exhibited the most favorable characteristics in the validation set, achieving an MCC of 0.7. ANXA1 contributed the most to the model that predicts UC. The optimal model was implemented on the website. Among UC patients receiving TNFα inhibitor treatment, the ineffective group showed considerably increased expression of the five critical genes than the responsive group.
conclusionBIRC3, IFITM2, ANXA1, ISG20, and MSN may serve as potential diagnostic biomarkers in UC. Through the interaction between characteristic biomarkers and immune infiltrating cells, the immune response mediated by these characteristic biomarkers plays a crucial role in the occurrence and development of UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.